Nav: Home

Immune 'cloaking' in cancer cells and implications for immunotherapy

September 16, 2020

Researchers at Queen Mary University of London, The Institute of Cancer Research, London, and the Moffitt Cancer Centre have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient's cancer, helping to guide treatment decisions.

A battle between cancer cells and immune cells

Immune cells recognise tumours by detecting molecules present on the surface of cancer cells, known as neoantigens. Neoantigens are 'faulty' molecules that are made as the result of changes to the genetic code (mutations) within cancer cells. When immune cells scan the body, they recognise these faulty molecules as being non-self, which triggers an immune response against the cancer.

In order to overcome destruction by the immune system, the cancer cells fight back by developing 'cloaking' mechanisms which they can use to hide from immune cells. Consequently, the cancer can continue to grow undetected within the body.

The team, led by Dr Eszter Lakatos and Professor Trevor Graham from Queen Mary University of London, and Professor Andrea Sottoriva from The Institute of Cancer Research (ICR), set out to develop a computational model to map the arms race that occurs between cancer cells and immune cells as tumours evolve. Using genomic data from bowel, stomach and endometrial cancers available from the Cancer Genome Atlas, the team developed a model that works out the interplay between the immune system and cancer cells using the genetic codes of cancer cells as its input. By calculating the number of neoantigens present in a tumour and looking at how fast they have accumulated, the model is able to predict when the cancer is likely to activate its cloaking mechanisms against the immune system.

Dr Lakatos from Queen Mary University of London said: "Mathematical modelling can help us re-create biological processes even when only a small part of the picture is available. It is especially useful in determining how a cancer developed, as we typically only see a single snapshot of that process. We developed our model to characterise all possible developing cancers - including the ones that are successfully destroyed by the immune system - to highlight what measurements are most informative about their future evolution."

The research was published today in Nature Genetics and primarily funded by Cancer Research UK, with additional support from Wellcome and the National Institutes of Health.

Considerations for immunotherapy

The predictions from the model may have important implications for immunotherapy sensitivity in patients with cancer. Immunotherapies are a group of drugs which boost the activity of the patient's immune system to help fight their cancer. Such drugs have been shown to be extremely effective against some cancer types, even achieving cure in some cases. However, this is not the case for all patients and not all tumours respond to immunotherapy. Being able to know ahead of time if immunotherapy is likely to be effective would be extremely valuable for patient management.

Professor Graham from Queen Mary University of London said: "Boosting the immune system is an incredibly effective way to treat cancer, but it has been difficult to understand why some patients respond to immunotherapy and others don't. Our study is a step towards understanding the interplay between immune cells and tumour cells, and we hope that this understanding might prove useful for guiding treatment decisions in the future."

The new mathematical model may help researchers make predictions about people's cancers, informing on whether immunotherapy is likely to be an effective treatment option for a patient based on the cancer cells' immune cloaking status. The model predicts that immunotherapy may be most effective when it is administered after a cancer has cloaked itself, as at this point the therapy could be used to reinvigorate the immune system to recognise and fight the cancer. The model also predicts that if the cancer has not activated immune cloaking mechanisms early on in its development, immunotherapy may be effective initially but the long-term response to the treatment may not be so successful.

Professor Sottoriva from The Institute of Cancer Research (ICR) said: "Our model helps us understand, through mathematics, the arms race that takes place within the body between a tumour and the patient's immune system. Cancers are constantly adapting and evolving - and can often dodge the effects of treatment or hide themselves from the immune system. Our study gives us a valuable tool for understanding and predicting how cancers will evolve and interact with the immune system, so we can anticipate cancer's next move, and devise new treatment strategies for patients."

The team has developed a model that expands the understanding of the action of the immune system on a tumour just from looking at the genetic codes of cancers. Because genetic analysis is becoming routine in the NHS, knowing how to use the genetic data to select patients for treatment and improve understanding of why immunotherapies are less effective in some patients than in others is very useful. The team are now keen to apply their model to cancers that have been treated with immunotherapy to see if the predictions are accurate.
-end-
Notes to editors

Research paper: Evolutionary dynamics of neoantigens in growing tumours. Eszter Lakatos, Marc J. Williams, Ryan O. Schenck, William C. H. Cross, Jacob, Househam, Luis Zapata, Benjamin Werner, Chandler Gatenbee, Mark Robertson-Tessi, Chris P. Barnes, Alexander R. A. Anderson, Andrea Sottoriva, Trevor A. Graham. Nature Genetics. DOI 10.1038/s41588-020-0687-1

Available here after the embargo lifts: https://www.nature.com/articles/s41588-020-0687-1

Queen Mary University of London

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.